SynthesisNeurology(R) neuroimmunology & neuroinflammation2022
Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy: Retrospective Study.
Synthesis in Neurology(R) neuroimmunology & neuroinflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Therapeutic effect of T-cell engager in two patients with autoimmune neuropathy.Nature communications · 2026Article
- Treatment of Anti-myelin-associated Glycoprotein Neuropathy with Tirabrutinib and a 3-year Follow-up.Internal medicine (Tokyo, Japan) · 2025Article
- Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments.Neurology. Clinical practice · 2025Article
- The Role of Complement Activation in IgM M-Protein-Associated Neuropathies.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Review
- Anti-MAG neuropathy: historical aspects, clinical-pathological correlations, and considerations for future therapeutical trials.Arquivos de neuro-psiquiatria · 2024Review
- Time course of the autoantibody response to therapy in anti-MAG neuropathy: TWO case REPORTS.Heliyon · 2024Article
- Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose.European journal of neurology · 2024Article
- Autoantibodies in neuromuscular disorders: a review of their utility in clinical practice.Frontiers in neurology · 2024Review
- Therapeutic Outcomes and Electrophysiological Biomarkers in Anti-Myelin-Associated Glycoprotein Neuropathy: A Multicenter Cohort Study in South Korea.Journal of clinical neurology (Seoul, Korea) · 2024Article
- A diagnostic score for anti-myelin-associated-glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti-myelin-associated-glycoprotein antibody.European journal of neurology · 2023Article
- Value of Antibody Determinations in Chronic Dysimmune Neuropathies.Brain sciences · 2022Review
- Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up.European journal of neurology · 2022Article
- Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib.Heliyon · 2022Article
- IgM monoclonal gammopathies of clinical significance: diagnosis and management.Haematologica · 2022Review
- Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy.Journal of neurology · 2022Article
- Immunoglobulin M Monoclonal Gammopathies of Clinical Significance.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThe objective of the retrospective analysis was to test the hypothesis that changes in serum anti-myelin-associated glycoprotein (MAG) autoantibodies are associated with clinical response to immunotherapy in patients with anti-MAG neuropathy.
methodsAs of January 29, 2020, we used anti-myelin-associated glycoprotein-related search strings in the Medline database to identify studies that provided information on anti-MAG immunoglobulin M (IgM) autoantibodies and clinical outcomes during immunotherapies. The relative change in anti-MAG IgM titers, paraprotein levels, or total IgM was determined before, during, or posttreatment, and the patients were assigned to "responder," "nonresponder,"' or "acute deteriorating" category depending on their clinical response to treatment. The studies were qualified as "supportive" or "not supportive" depending on the percentage of patients exhibiting an association between relative change of anti-MAG antibody titers or levels and change in clinical outcomes.
resultsFifty studies with 410 patients with anti-MAG neuropathy were included in the analysis. Forty studies with 303 patients supported the hypothesis that a "responder" patient had a relative reduction of anti-MAG antibody titers or levels that is associated with clinical improvements and "nonresponder" patients exhibited no significant change in anti-MAG IgM antibodies. Six studies with 93 patients partly supported, and 4 studies with 26 patients did not support the hypothesis. DISCUSSION: The retrospective analysis confirmed the hypothesis that a relative reduction in serum anti-MAG IgM antibodies is associated with a clinical response to immunotherapies; a sustained reduction of at least 50% compared with pretreatment titers or levels could be a valuable indicator for therapeutic response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.